drugset / Trial / NCT00551356

Lispro Mix 25 vs. Glargine in Type 2 Diabetics

NCT00551356

Phase 3 Completed 53 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment regiment with consisting of one time daily injection of insulin glargine. Improved glycemic control will be compared by the fasting plasma glucose and blood glucose excursions 2 hours after breakfast.

Timeline

Start
2002-11
Primary completion
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Mix25 Unknown Subcutaneous
Comparator insulin glargine Protein / enzyme biologic Subcutaneous